OMERS ADMINISTRATION Corp Acquires Shares of 81,400 Personalis, Inc. (NASDAQ:PSNL)

OMERS ADMINISTRATION Corp purchased a new stake in shares of Personalis, Inc. (NASDAQ:PSNL) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 81,400 shares of the company’s stock, valued at approximately $470,000.

A number of other large investors have also recently modified their holdings of the company. Lightspeed Management Company L.L.C. bought a new stake in shares of Personalis in the 4th quarter valued at about $47,169,000. Blue Water Life Science Advisors LP lifted its stake in shares of Personalis by 13.3% during the 4th quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company’s stock worth $6,548,000 after purchasing an additional 132,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Personalis by 144.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock valued at $2,372,000 after buying an additional 242,141 shares in the last quarter. Jane Street Group LLC grew its position in shares of Personalis by 144.3% in the 4th quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock worth $2,320,000 after buying an additional 237,033 shares during the last quarter. Finally, abrdn plc purchased a new position in Personalis in the fourth quarter worth $1,722,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Personalis in a research report on Thursday, April 10th. Craig Hallum assumed coverage on shares of Personalis in a research note on Monday, March 17th. They set a “buy” rating and a $8.00 price objective for the company. Guggenheim started coverage on Personalis in a research report on Thursday. They issued a “buy” rating and a $6.00 target price on the stock. Finally, HC Wainwright raised their price objective on Personalis from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, May 7th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $7.67.

Personalis Stock Up 1.2%

Personalis stock opened at $4.95 on Monday. The business’s 50-day moving average price is $3.76 and its 200 day moving average price is $4.45. The firm has a market cap of $437.21 million, a price-to-earnings ratio of -2.95 and a beta of 1.83. Personalis, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Equities analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.